SARS-COV-2 rbd subunit vaccine
SARS-COV-2 rbd subunit vaccine has been studied in 1 paper since 2021: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Nov 17, 2021: “An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice”.
1 paper studies itUpdated
See all 1 papers on SARS-COV-2 rbd subunit vaccine
- Animals1
Latest
Science Translational Medicine
An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice
Experiments in miceInterventions